Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
11.50    0.50 (4.55%)
Bid:
11.00
Ask:
12.00
Spread: 1.00 (9.091%)
Market Cap: £14.39m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Acquisition

30 Apr 2007 07:03

Fabian Romania Property Fund Ltd30 April 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or the "Fund") Fabian Romania announces the purchase of a €60 million office building inBucharest Fabian Romania has reached agreement to purchase its fourth office project, theCubic office development (the "Cubic Centre"), in Bucharest. The Cubic Centrewill be a class A office building with a gross area of approximately 44,000square metres, located in North Bucharest. The building is being developed bythe Kendama, an experienced local developer in Romania. Construction hascommenced and completion is anticipated in the second quarter of 2009. The Cubic Centre will upon completion of construction provide a net lettableoffice area of 27,000 square metres over 12 floors, together with 533 carspaces. The building is located in a prominent location in the Pipera districtof North Bucharest and is likely to attract international tenants seeking classA office space. Vacancy rates for class A office space in in Bucharest are lessthan 3%. The acquisition is due to complete, subject to certain conditions, in twostages. The Fund will pay a first instalment of €12.25 million, of which €5million has already been paid in the form of a secured loan. At practicalcompletion of the building by the developer, the Fund will pay the finalinstalment based upon a forward purchase yield of 7.4% - 7.8% applied to rentsachieved. Based upon current rental estimates, the total value of thetransaction is estimated to be approximately of €60 million. The total equityrequirement for the fund is estimated to be €12 million. Commenting on the transaction, Mark Holdsworth, Managing Director of FabianCapital, the Investment Advisor to the Fund said: "We are delighted that the Fund has sealed its first investment since Admissionto AIM on favourable terms in what is a highly competitive market. The CubicCentre will provide a high quality addition to the Fund's portfolio of officebuildings. It will also give diversification geographically within the city bothin terms of building type and expected tenant mix." Mark Owen, Director responsible for acquisitions comments: "The new office development is in a prominent location in the rapidly expandingoffice location of the northern Pipera district of the City. This area will befurther enhanced by the new motorway link into the City. The Cubic Centre,which is already under construction on a fixed price basis, is well positionedto capitalise on the demand for Class A office space expected. We are already inearly discussions with a number of quality tenants seeking to upgrade theiroffice accommodation." The lead advisers on the transaction were Eurisko (property agent), WSP(technical advisers) and NNDKP (legal adviser). END For Comments:Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLP +44 20 7936 3000James Lewis Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Jun 20233:34 pmRNSHolding(s) in Company
12th Jun 202311:02 amRNSDirector/PDMR Shareholding
8th Jun 202310:39 amRNSResult of GM and total voting rights
31st May 20235:00 pmRNSTotal Voting Rights
26th May 20234:57 pmRNSHolding(s) in Company
26th May 20231:33 pmRNSHolding(s) in Company
23rd May 20237:00 amRNSResult of Retail Offer and Notice of GM
19th May 202310:01 amRNSREX Retail Offer
19th May 202310:00 amRNSPlacing, Subscription and Retail Offer
3rd Apr 20237:00 amRNSBlock listing Interim Review
31st Mar 20237:00 amRNSChange of Registered Office
21st Mar 20237:00 amRNSPatent application
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
6th Mar 20237:00 amRNSTrading Statement
9th Feb 20237:00 amRNSR&D update: Mammalian Display service
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 202311:05 amRNSSecond Price Monitoring Extn
9th Jan 202311:00 amRNSPrice Monitoring Extension
5th Dec 20227:00 amRNSHalf-year Report
24th Nov 20227:00 amRNSNotice of Results
31st Oct 20221:47 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSBlock admission six monthly return
23rd Sep 202211:44 amRNSResult of AGM
20th Sep 20221:36 pmRNSDirector/PDMR Shareholding
15th Sep 20223:41 pmRNSGrant of options
14th Sep 20222:05 pmRNSSecond Price Monitoring Extn
14th Sep 20222:01 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSGrant of options
1st Sep 20227:00 amRNSNotice of AGM and Director change
23rd Aug 20227:00 amRNSFinal Results
9th Aug 20227:00 amRNSBispecific designs patent application
5th Aug 20224:41 pmRNSSecond Price Monitoring Extn
5th Aug 20224:35 pmRNSPrice Monitoring Extension
28th Jul 20227:00 amRNSAppointment of Chief Executive Officer
6th May 20227:00 amRNSTrading update
1st Apr 20227:00 amRNSBlock admission six monthly return
14th Mar 20227:00 amRNSUpdate on Board changes
28th Feb 20227:00 amRNSDirector changes
22nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20224:35 pmRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSDirectorate Change
10th Feb 202212:49 pmRNSStmnt re Share Price Movement
14th Jan 20227:00 amRNSFormation of New Scientific Advisory Panel
11th Jan 20221:26 pmRNSHolding(s) in Company
31st Dec 20217:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSExercise of share options and total voting rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.